Beata Sweryda-Krawiec, Ph.D. is a pharmaceutical scientist with over 20 years of R&D experience at companies including Boehringer Ingelheim, ImmunoGen, Tarveda Therapeutics, Cerulean Pharma, Amgen, and Novartis. Her expertise spans analytical development, drug delivery systems, and CMC strategies for small molecules, biologics, ADCs, and nanoparticle-based therapies.

Currently Associate Director of External Alternative CMC Development at Boehringer Ingelheim, Beata leads analytical strategies from early development through clinical stages. Throughout her career, she has contributed to multiple INDs and BLAs, with a strong track record in DS/DP development, analytical method transfer, solid-state form selection, and regulatory submissions. Her experience includes managing complex projects involving highly potent APIs and drug-delivery products.

Beata has led successful CDMO collaborations and introduced innovative CMC approaches to streamline development. An active member of AAPS, she has held leadership roles and continues to advocate for advancing analytical science in support of transformative therapies.